To support the launch of Nourianz, an innovative adenosine inhibitor developed to treat Parkinson’s disease, GRAFX Co. partnered with healthcare agency Pixacore to produce a clear, visually engaging Mechanism of Action (MOA) animation tailored for medical professionals.
Project
Nourianz Adenosine Inhibitor MOA
Client
Pixacore
Our Role
3D/2.5D Animation
In Parkinson’s patients, overstimulation of the brain’s indirect pathway by adenosine can disrupt normal dopamine signaling—leading to the characteristic motor symptoms of the disease. Nourianz works by blocking adenosine receptors, helping to restore balance and improve physical movement. Our animation breaks down this complex neurological process into a digestible visual narrative, aiding physicians in understanding how Nourianz works at a molecular level.
